ARK Investment Management LLC Raises Stock Holdings in Gamida Cell Ltd. (NASDAQ:GMDA)

ARK Investment Management LLC raised its position in shares of Gamida Cell Ltd. (NASDAQ:GMDA) by 51.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,144,422 shares of the company’s stock after buying an additional 724,806 shares during the quarter. ARK Investment Management LLC’s holdings in Gamida Cell were worth $885,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of GMDA. JPMorgan Chase & Co. raised its stake in Gamida Cell by 12.8% during the first quarter. JPMorgan Chase & Co. now owns 731,328 shares of the company’s stock valued at $3,035,000 after buying an additional 83,009 shares in the last quarter. Federated Hermes Inc. raised its stake in Gamida Cell by 17.5% during the first quarter. Federated Hermes Inc. now owns 5,128,300 shares of the company’s stock valued at $21,282,000 after buying an additional 764,985 shares in the last quarter. Mariner LLC raised its stake in Gamida Cell by 8.3% during the first quarter. Mariner LLC now owns 621,334 shares of the company’s stock valued at $2,579,000 after buying an additional 47,587 shares in the last quarter. Bank of America Corp DE raised its stake in Gamida Cell by 539.0% during the first quarter. Bank of America Corp DE now owns 15,214 shares of the company’s stock valued at $63,000 after buying an additional 12,833 shares in the last quarter. Finally, FMR LLC raised its stake in Gamida Cell by 0.9% during the second quarter. FMR LLC now owns 4,630,125 shares of the company’s stock valued at $8,195,000 after buying an additional 42,421 shares in the last quarter. Institutional investors and hedge funds own 50.34% of the company’s stock.

Gamida Cell Stock Down 82.7 %

Shares of Gamida Cell stock opened at $0.06 on Thursday. Gamida Cell Ltd. has a twelve month low of $0.05 and a twelve month high of $2.51. The company has a current ratio of 3.32, a quick ratio of 3.20 and a debt-to-equity ratio of 213.14. The business’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $0.51.

Analyst Upgrades and Downgrades

GMDA has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Gamida Cell in a research note on Tuesday, December 5th. JMP Securities reiterated a “market perform” rating on shares of Gamida Cell in a research report on Monday, January 29th.

About Gamida Cell

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.